Barclays raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $28 from $16 and keeps an Overweight rating on the shares after the company reported positive Phase 1 data for soquelitinib in atopic dermatitis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Corvus Pharmaceuticals price target raised to $20 from $13 at Mizuho
- Midday Fly By: Netflix and Warner amend deal, GSK to acquire Rapt
- Corvus Pharmaceuticals: Undervalued Buy on Soquelitinib’s Promising Data, Expanding Immunology Pipeline, and Multiple Upcoming Catalysts
- Corvus Pharmaceuticals price target raised to $27 from $11 at H.C. Wainwright
- Corvus Pharmaceuticals reports positive Phase 1 soquelitinib results